Recently, NSK and its partner Cyfuse have successfully developed new technologies that can be applied to the next-generation growth fields of regenerative medicine, cell medicine, drug development and healthcare (hereinafter referred to as the field), which will help the clinical application and commercial production of new cell products in this field.
The new technology is based on Cyfuse’s unique biological 3D printing technology and combines NSK’s superior technology in the field of industrial machinery – “mechatronics technology” characterized by precision positioning technology through the development and cultivation of precision equipment. With this powerful combination, the research and development technology carried by Cyfuse’s biological 3D printer “S-PIKE®” (product name: S-PIKE) has been further strengthened and applied and developed into a commercial production technology suitable for 3D cell products.
As NSK and Cyfuse further develop their respective technologies in their respective fields, it is foreseeable that various process automation technologies, devices, and equipment involved in the product manufacturing process will be further improved, and both parties will continue to work on technological innovations that improve the production efficiency and quality of products such as regenerative medicine and innovative 3D cell products such as human 3D mini livers*.
In the future, NSK and Cyfuse will continue to strengthen and expand their friendly and cooperative partnership, collaborate with partners in various fields, and jointly create products and services that will help expand and develop related fields.
■ Cyfuse Company Introduction
Cyfuse is a regenerative medicine company whose unique bio 3D printing technology enables three-dimensional modeling with only cells. The company has always been committed to promoting the development of regenerative medicine products and putting them into practical use as a new treatment method.
At present, the development of regenerative medicine technology using Cyfuse bio 3D printers has entered the clinical development stage for patient transplantation, and is actively carrying out the construction and establishment of a business platform (supply chain) in this field to fully prepare for future commercial production.
※: Cyfuse uses its unique basic technology to extract some tissues in the human body and replicate them in vitro, successfully realizing the commercialization of the world’s first “Functional Cellular Device” (FCD), and launched the innovative product “Human 3D Mini Liver”. Compared with traditional products, this product is closer to the structure and function of a living liver, further meeting the needs of pharmaceutical companies and non-clinical trial outsourcing companies in new drug research and development, and can be used as a substitute for animal experiments in the future. It will have great social significance in terms of sustainable development and has attracted much attention from all walks of life.